DIADEMA PARTNERS LP — 13F Holdings & Portfolio
CIK 2026172 · latest 13F-HR filed 2026-08-14
DIADEMA PARTNERS LP manages $791.3M in 13F-reported U.S. long-equity assets across 149 reported positions as of its 2026-06-30 13F-HR filing. Its largest disclosed positions are VKTX (6.02%), ABVX (5.88%), BMY (4.37%). Quarter over quarter (versus its 2026-03-31 filing) the fund opened 29 new positions and exited 37; 30 existing positions rose in reported value and 15 fell.
AUM is the long-equity portion reported on Form 13F-HR. Excludes short positions, cash, foreign holdings, and non-13F assets. For informational purposes only — not investment advice.
Long-equity book
Distinct positions
Filed 2026-08-14
vs 2026-03-31
Portfolio charts
Latest quarter's book, what changed, and how the portfolio has evolved across filings.
Portfolio map
Q2 26Box size = position value; colour = change in share count vs the prior quarter (green added, red trimmed, blue new). Rows split across managers or share classes are combined. Click a box for the stock.
Sector mix
% of 13F valueSectors from each company's SIC code; funds and ETFs grouped separately.
Biggest buys and sells
Q1 26 → Q2 26Estimated from the change in shares held × the quarter-end price, so price moves alone don't count as buying. New and exited positions are included.
13F assets and positions
4 quartersTotal reported 13F value (bars) and number of positions (line) each quarter. Value changes include market moves.
Top positions over time
reported valueThe eight largest current positions, valued at each quarter end.
Concentration
top 10 = 62.5%Cumulative share of the portfolio held in the largest N positions.
As of the firm’s regulatory filing dated Mar 20, 2026.
EAST TOWER 2ND FLOOR
MORRISTOWN, NJ 07960
| Name | Title / Status | Ownership | Type |
|---|---|---|---|
| BASSETT, TIMOTHY, BEAU Control | CHIEF INVESTMENT OFFICER, LIMITED PARTNER since Apr 2024 | 75% or more | Individual |
| Canonico, Zachary, Kayn Control | CHIEF OPERATING OFFICER, CHIEF COMPLIANCE OFFICER since Apr 2024 | Less than 5% | Individual |
| DIADEMA PARTNERS GENERAL PARTNER LLC Control | GENERAL PARTNER since Apr 2024 | Less than 5% | Domestic Entity |
| BASSETT, TIMOTHY, BEAU Control Indirect owner via DIADEMA PARTNERS GENERAL PARTNER LLC | MANAGING MEMBER since Apr 2024 | 75% or more | Individual |
Quarter-over-quarter changes
Changes in reported position value vs the prior 13F, so price moves count too, not just shares bought or sold.
Top Adds (vs prior quarter)
- REVOLUTION MEDICINES INC$18.2M +231.5%
- ABIVAX SA$13.4M +162.8%
- UNITED THERAPEUTICS CORP DEL$12.5M +77.3%
- BIOMARIN PHARMACEUTICAL INC$9.5M +113.8%
- COGENT BIOSCIENCES INC$6.7M +53.8%
Top Trims
- JOHNSON & JOHNSON-$7.6M -57.5%
- HARMONY BIOSCIENCES HLDGS IN-$1.6M -62.4%
- CORBUS PHARMACEUTICALS HLDGS-$1.3M -31.6%
- MONTE ROSA THERAPEUTICS INC-$1.2M -38.4%
- AYTU BIOPHARMA INC-$644.5K -66.9%
New Positions
- EDGEWISE THERAPEUTICS INC$11.1M
- 4D MOLECULAR THERAPEUTICS IN$7.6M
- RELAY THERAPEUTICS INC$4.3M
- TAYSHA GENE THERAPIES INC$3.6M
- NURIX THERAPEUTICS INC$2.9M
Exited Positions
- JAZZ PHARMACEUTICALS PLC$10.4M
- TERNS PHARMACEUTICALS INC$9.6M
- INCYTE CORP$7.3M
- TG THERAPEUTICS INC$6.9M
- BRIDGEBIO PHARMA INC$6.3M
DIADEMA PARTNERS LP Holdings (2026-06-30)
Rows tagged Call or Put are options positions, not stock. Per SEC Form 13F-HR, Value shows the notional value of the underlying (shares covered × underlying price), not the option premium. Shares is the number of underlying shares covered (divide by 100 for contract count).
| # | Issuer | Symbol | CUSIP | Value | Weight | Shares | Type |
|---|---|---|---|---|---|---|---|
| 1 | VIKING THERAPEUTICS INC Call | VKTX | 92686J106 | $47.6M | 6.02% | 1,220,800 | SH |
| 2 | ABIVAX SA Call | ABVX | 00370M103 | $46.5M | 5.88% | 349,200 | SH |
| 3 | BRISTOL-MYERS SQUIBB CO Call | BMY | 110122108 | $34.6M | 4.37% | 600,000 | SH |
| 4 | ABIVAX SA Put | ABVX | 00370M103 | $33.6M | 4.25% | 252,400 | SH |
| 5 | UNITED THERAPEUTICS CORP DEL | UTHR | 91307C102 | $28.7M | 3.63% | 52,989 | SH |
| 6 | REVOLUTION MEDICINES INC | RVMD | 76155X100 | $26.1M | 3.29% | 139,218 | SH |
| 7 | ABIVAX SA | ABVX | 00370M103 | $21.6M | 2.73% | 163,644 | SH |
| 8 | COGENT BIOSCIENCES INC | COGT | 19240Q201 | $19.1M | 2.41% | 493,664 | SH |
| 9 | BRISTOL-MYERS SQUIBB CO Put | BMY | 110122108 | $19.0M | 2.41% | 330,600 | SH |
| 10 | BRIDGEBIO PHARMA INC | BBIO | 10806XAJ1 | $18.6M | 2.35% | 250,000 | PRN |
| 11 | CORCEPT THERAPEUTICS INC Call | CORT | 218352102 | $17.9M | 2.27% | 206,300 | SH |
| 12 | BIOMARIN PHARMACEUTICAL INC | BMRN | 09061G101 | $17.9M | 2.26% | 312,846 | SH |
| 13 | VIKING THERAPEUTICS INC | VKTX | 92686J106 | $17.2M | 2.18% | 441,808 | SH |
| 14 | KYMERA THERAPEUTICS INC Call | KYMR | 501575104 | $17.2M | 2.17% | 149,700 | SH |
| 15 | NOVARTIS AG Put | NVS | 66987V109 | $15.7M | 1.98% | 100,000 | SH |
| 16 | UNIQURE NV Put | QURE | N90064101 | $13.8M | 1.74% | 299,000 | SH |
| 17 | VIKING THERAPEUTICS INC Put | VKTX | 92686J106 | $13.7M | 1.73% | 350,500 | SH |
| 18 | BIOGEN INC Call | BIIB | 09062X103 | $13.0M | 1.64% | 60,000 | SH |
| 19 | CAPRICOR THERAPEUTICS INC Put | CAPR | 14070B309 | $12.9M | 1.63% | 534,400 | SH |
| 20 | SUMMIT THERAPEUTICS INC Call | SMMT | 86627T108 | $12.5M | 1.58% | 860,200 | SH |
| 21 | ELI LILLY & CO Put | LLY | 532457108 | $12.0M | 1.52% | 10,000 | SH |
| 22 | INCYTE CORP Put | INCY | 45337C102 | $11.9M | 1.51% | 105,400 | SH |
| 23 | EDGEWISE THERAPEUTICS INC | EWTX | 28036F105 | $11.1M | 1.40% | 272,214 | SH |
| 24 | UNIQURE NV Call | QURE | N90064101 | $10.8M | 1.37% | 235,400 | SH |
| 25 | BIONTECH SE Call | BNTX | 09075V102 | $9.3M | 1.18% | 100,000 | SH |
| 26 | KODIAK SCIENCES INC | KOD | 50015M109 | $8.5M | 1.07% | 218,117 | SH |
| 27 | IMMUNOCORE HLDGS PLC | IMCR | 45258D105 | $8.1M | 1.02% | 254,863 | SH |
| 28 | CAPRICOR THERAPEUTICS INC Call | CAPR | 14070B309 | $7.9M | 1.00% | 329,300 | SH |
| 29 | NOVARTIS AG Call | NVS | 66987V109 | $7.8M | 0.99% | 50,000 | SH |
| 30 | REPLIMUNE GROUP INC Call | REPL | 76029N106 | $7.7M | 0.97% | 696,300 | SH |
| 31 | KODIAK SCIENCES INC Call | KOD | 50015M109 | $7.7M | 0.97% | 196,700 | SH |
| 32 | 4D MOLECULAR THERAPEUTICS IN | FDMT | 35104E100 | $7.6M | 0.96% | 571,107 | SH |
| 33 | MODERNA INC Put | MRNA | 60770K107 | $7.0M | 0.88% | 100,000 | SH |
| 34 | HIMS & HERS HEALTH INC Call | HIMS | 433000106 | $6.9M | 0.88% | 200,000 | SH |
| 35 | ARCUS BIOSCIENCES INC | RCUS | 03969F109 | $6.9M | 0.87% | 223,810 | SH |
| 36 | HIMS & HERS HEALTH INC Put | HIMS | 433000106 | $6.7M | 0.85% | 193,700 | SH |
| 37 | CORBUS PHARMACEUTICALS HLDGS Call | CRBP | 21833P301 | $5.9M | 0.75% | 633,800 | SH |
| 38 | SELLAS LIFE SCIENCES GROUP I Call | SLS | 81642T209 | $5.9M | 0.75% | 400,000 | SH |
| 39 | KODIAK SCIENCES INC Put | KOD | 50015M109 | $5.7M | 0.72% | 146,900 | SH |
| 40 | ALUMIS INC Call | ALMS | 022307102 | $5.6M | 0.71% | 200,000 | SH |
| 41 | ROYALTY PHARMA PLC Call | RPRX | G7709Q104 | $5.6M | 0.71% | 100,000 | SH |
| 42 | JOHNSON & JOHNSON | JNJ | 478160104 | $5.6M | 0.71% | 22,000 | SH |
| 43 | REPLIMUNE GROUP INC Put | REPL | 76029N106 | $5.6M | 0.70% | 502,500 | SH |
| 44 | BIOAGE LABS INC Call | BIOA | 09077V100 | $4.9M | 0.62% | 200,100 | SH |
| 45 | NOVO-NORDISK A S | NVO | 670100205 | $4.8M | 0.61% | 100,000 | SH |
| 46 | BIOHAVEN LTD Call | BHVN | G1110E107 | $4.7M | 0.60% | 317,000 | SH |
| 47 | TENAX THERAPEUTICS INC Call | TENX | 88032L605 | $4.5M | 0.56% | 307,000 | SH |
| 48 | CORVUS PHARMACEUTICALS INC | CRVS | 221015100 | $4.4M | 0.56% | 294,811 | SH |
| 49 | RELAY THERAPEUTICS INC | RLAY | 75943R102 | $4.3M | 0.55% | 230,677 | SH |
| 50 | TG THERAPEUTICS INC Call | TGTX | 88322Q108 | $4.2M | 0.53% | 75,700 | SH |
| Period | Filed | AUM | Holdings | Accession |
|---|---|---|---|---|
| 2026-06-30 | 2026-08-14 | $791.3M | 149 | 0001892688-26-000119 |
| 2026-03-31 | 2026-05-15 | $587.7M | 144 | 0001892688-26-000076 |
| 2025-12-31 | 2026-02-17 | $580.5M | 145 | 0001892688-26-000036 |
| 2025-09-30 | 2025-11-14 | $391.0M | 130 | 0001892688-25-000193 |
EAST TOWER, 2ND FLOOR
MORRISTOWN, NJ 07960